Division of Life Science, Hong Kong University of Science and Technology, Hong Kong SAR, China.
Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Hong Kong SAR, China.
Clin Chem. 2022 Sep 1;68(9):1184-1195. doi: 10.1093/clinchem/hvac097.
BACKGROUND: Cell-free DNA (cfDNA) is emerging as a biomarker for sepsis. Previous studies have been focused mainly on identifying blood infections or simply quantifying cfDNA. We propose that by characterizing multifaceted unexplored components, cfDNA could be more informative for assessing this complex syndrome. METHODS: We explored multiple aspects of cfDNA in septic and nonseptic intensive care unit (ICU) patients by metagenomic sequencing, with longitudinal measurement and integrative assessment of plasma cfDNA quantity, human cfDNA fragmentation patterns, infecting pathogens, and overall microbial composition. RESULTS: Septic patients had significantly increased cfDNA quantity and altered human cfDNA fragmentation pattern. Moreover, human cfDNA fragments appeared to comprise information about cellular oxidative stress and could indicate disease severity. Metagenomic sequencing was more sensitive than blood culture in detecting bacterial infections and allowed for simultaneous detection of viral pathogens. We found differences in microbial composition between septic and nonseptic patients and between survivors and nonsurvivors by 28-day mortality, both on the first day of ICU admission and across the study period. By integrating all the information into a machine learning model, we achieved improved performance in identifying sepsis and prediction of clinical outcome for ICU patients with areas under the curve of 0.992 (95% CI 0.969-1.000) and 0.802 (95% CI 0.605-0.999), respectively. CONCLUSIONS: We were able to diagnose sepsis and predict mortality as soon as the first day of ICU admission by integrating multifaceted cfDNA information obtained in a single metagenomic assay; this approach could provide important advantages for clinical management and for improving outcomes in ICU patients.
背景:游离 DNA(cfDNA)作为败血症的生物标志物正在兴起。先前的研究主要集中在识别血液感染或简单地定量 cfDNA 上。我们提出,通过对多方面未被探索的成分进行特征描述,cfDNA 可以为评估这种复杂的综合征提供更多信息。
方法:我们通过宏基因组测序探索了败血症和非败血症重症监护病房(ICU)患者 cfDNA 的多个方面,对血浆 cfDNA 量、人类 cfDNA 片段化模式、感染病原体和整体微生物组成进行了纵向测量和综合评估。
结果:败血症患者的 cfDNA 量显著增加,且人类 cfDNA 片段化模式发生改变。此外,人类 cfDNA 片段似乎包含有关细胞氧化应激的信息,并可能表明疾病的严重程度。宏基因组测序在检测细菌感染方面比血液培养更敏感,并且可以同时检测病毒病原体。我们通过 28 天死亡率发现了败血症和非败血症患者以及幸存者和非幸存者之间的微生物组成差异,无论是在 ICU 入院的第一天还是在整个研究期间。通过将所有信息整合到机器学习模型中,我们提高了识别败血症和预测 ICU 患者临床结局的性能,曲线下面积分别为 0.992(95%CI 0.969-1.000)和 0.802(95%CI 0.605-0.999)。
结论:我们能够通过整合单次宏基因组检测获得的多方面 cfDNA 信息,在 ICU 入院的第一天即可诊断败血症并预测死亡率;这种方法可能为临床管理提供重要优势,并改善 ICU 患者的预后。
J Vet Emerg Crit Care (San Antonio). 2018-11
Open Forum Infect Dis. 2025-8-12
Signal Transduct Target Ther. 2025-3-19
Front Cell Infect Microbiol. 2025-2-19
Acta Derm Venereol. 2025-1-3
Mater Today Bio. 2024-11-25